Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 healthy volunteer study of P-gp interactions with ASTX660
NL-OMON50115Phase 1Completed
- Sponsor
- Astex Pharmaceuticals
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tolinapant, quinidine and fexofenadine, sponsored by Astex Pharmaceuticals. Primary endpoints: Effect of quinidine on ASTX660 pharmacokinetics and Effect of ASTX660 on fexofenadine pharmacokinetics. Started Sep 2021; status: completed.
02
Drugs
tolinapantquinidinefexofenadine
Beyond the preview
Go deeper on NL-OMON50115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50115.